CDMO industry development space is huge, head enterprises to accelerate the layout into a trend!

【Pharmaceutical Network Industry News】Recently, Kailaiying released the news that on September 26, it signed the "Investment Agreement on Investing in the Construction of "Biomedical R&D and Production Integrated Base Project" with the Administrative Committee of Taixing Economic Development Zone of Jiangsu Province (hereinafter referred to as "Taixing Management Committee"), and intends to invest 4-5 billion yuan to build a biomedical R&D and production integration base project
in Taixing.

The project plan will be the overall design, phased construction, the project construction content for small molecule CDMO chemical raw materials and APIs research and development and production
.

CDMO industry development space is huge, head enterprises to accelerate the layout into a trend! (Image source: Pharmaceutical Network) In fact, before the signing of the investment agreement, Kailai Ying had already laid out a biopharmaceutical production base
in Shanghai.

Specifically, in March this year, Kailai Ying signed an investment agreement with Shanghai Industrial Comprehensive Development Zone Co.
, Ltd.
and invested in a newly established wholly-owned subsidiary to invest in the construction of a biopharmaceutical CDMO R&D and commercial production base
in Shanghai Fengxian with its own or self-raised funds of 3 billion yuan.

This means that Gloria Ying has spent 7-8 billion yuan on CDMO industry investment
this year.

The industry believes that its optimism about the pharmaceutical CDMO service industry is self-evident
.

It is understood that CDMO is one of the subdivisions of CXO, and it is also a popular and booming track in recent years, and its business is mainly to help innovative drug companies produce and manufacture new drugs
.

With the vigorous development of the global innovative drug industry, the field of pharmaceutical service outsourcing is ushering in a huge space for development in recent years, and the market size is also expanding
.

Some institutions predict that by 2025, the scale of the domestic CDMO industry will exceed the mark of 120 billion yuan, with a compound growth rate of more than 31%.


In fact, in the face of such a considerable market, many companies can imagine the layout of the CDMO field
.

It is understood that in addition to Gloria Young, the topping out ceremony of the R&D building of the CDMO global innovative drug service platform project of Puluo Pharmaceutical has also been successfully held
.

It is reported that the CDMO R&D building covers an area of 2501 square meters, with a total construction area of 13195 square meters, a total of five floors, and is expected to be put into use
by the end of the first quarter of 2023.

After the completion of the project, it will meet the needs of the CDMO R&D team of more than 500 people in Puluo Pharmaceutical
.

On September 26, Haixiang Pharmaceutical announced that the company deliberated and passed the "Proposal on Investment and Construction of Headquarters Research Institute" on the same day, and intends to invest in the construction of headquarters research institute projects
in Jiaojiang District, Taizhou City.

On September 25, Opmeer issued an announcement that it intends to raise 321 million yuan of IPO funds to increase the capital of its subsidiary Opramer Bioengineering; Purmai said that the purpose of the capital increase is to further strengthen the company's optimization and upgrading in the CDMO business field and improve the service level of
CDMO biopharmaceutical industrialization.

In addition, Medici also said in a survey some time ago that CDMO/CMO is the company's future efforts to focus on the direction of expansion, the company plans to expand the CDMO service level, through strategic cooperation, self-construction or mergers and acquisitions, to establish a large-scale production base in line with GMP standards.
.
.
It can be clearly seen from the above that the global CDMO industry is currently in a golden period
of a new round of pharmaceutical research and development.

With the vigorous development of the CDMO market and the iterative expansion of market demand, relevant enterprises are further extending the depth and breadth
of CDMO business through base construction and acquisition.

In the future, the industry is expected to have high-tech development optimization capabilities, industrial chain vertical extension of innovative service enterprises or will win the future
.

It should be noted that in the context of changes in the pharmaceutical industry, the situation of customer projects slimming down and budget reduction will also lead to changes in the CDMO industry and intensified
competition.

Therefore, the industry recommends that companies continue to recruit executives with experience in drug research and development and continue to cultivate core teams to strive for more advantages
in market competitiveness.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.